WS #16536
Bristol Myers Squibb reported a Q3 earnings beat but issued cautious guidance, warning of a $1.5B-$2B Eliquis step-down in 2027, which has tempered investor enthusiasm. Conversely, Biogen saw its price target raised by UBS, reflecting confidence in its pipeline. The mixed results highlight the divergent paths within the pharmaceutical sector, with patent cliffs posing a significant overhang for some while others find growth in new therapies. Norwegian Cruise Line Holdings shares surged 13% after reporting higher-than-expected third-quarter earnings and raising its full-year guidance. The company cited strong demand for cruises and effective cost management, signaling resilience in the consumer discretionary sector despite broader economic headwinds. This performance contrasts with the tech selloff, offering a rare bright spot in an otherwise risk-off market environment.
Pharmaceutical Earnings
Bristol Myers Squibb reported a Q3 earnings beat but issued cautious guidance, warning of a $1.5B-$2B Eliquis step-down in 2027, which has tempered investor enthusiasm. Conversely, Biogen saw its price target raised by UBS, reflecting confidence in its pipeline. The mixed results highlight the divergent paths within the pharmaceutical sector, with patent cliffs posing a significant overhang for some while others find growth in new therapies.
Norwegian Cruise Line Holdings shares surged 13% after reporting higher-than-expected third-quarter earnings and raising its full-year guidance. The company cited strong demand for cruises and effective cost management, signaling resilience in the consumer discretionary sector despite broader economic headwinds. This performance contrasts with the tech selloff, offering a rare bright spot in an otherwise risk-off market environment.